| Document |
Document Title |
|
WO/2020/243488A1 |
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7a, R7a, R11a, R11b, R12a, R12b, R16a, R16b, R19, R11a, R22, RX, RY and n are defined he...
|
|
WO/2020/223174A1 |
Provided are androstane and dihydrotestosterone compounds functionalized with carbocyclic groups or heterocyclic groups that may be saturated or unsaturated. The compounds may be used in methods of inhibiting cell growth of malignant cel...
|
|
WO/2020/210907A1 |
The present disclosure relates to processes for recovering valuable products from Fabaceae family plant fractions, in particular from Medicago sativa ssp. The processes disclosed herein include processes for obtaining macrofibers, microf...
|
|
WO/2020/198878A1 |
The present application provides compounds, compositions and methods to reduce, alleviate or treat various enteric diseases and disorders, such as inflammatory bowel disease. The compounds are xyloglucan-containing prodrugs, referred to ...
|
|
WO/2020/185610A1 |
The present disclosure is concerned with taccalonolide analogs and conjugated taccalonolide analogs useful as cellular probes and in the treatment of, for example, hyperproliferative disorders such as cardiovascular diseases and cancer. ...
|
|
WO/2020/146541A2 |
Provided herein are compounds, compounds including traceless linkers, protein conjugates thereof, and compositions thereof. Also provided herein are methods for the treatment of diseases, disorders, and conditions, and/or the management ...
|
|
WO/2020/128514A1 |
2-Fluorinated bile acid compounds of general formula (I) wherein at least one of R1 and R2 represents F and the other is chosen 3 from H and F and wherein R3 is as defined herein; are of use in the treatment and prevention of neurodegene...
|
|
WO/2020/115371A1 |
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof (I) wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in treatment or ...
|
|
WO/2020/092972A1 |
Provided herein are steroid sulfatase inhibitor compounds and androgen receptor inhibitor compounds that can be useful in, for example, the treatment of cancers such as prostate cancer and breast cancer. Pharmaceutical compositions and k...
|
|
WO/2020/082527A1 |
Disclosed is a process for extracting saponin from a plant. The preparation step thereof comprises: 1) adding an acid or a petroleum ether solvent and an acid to saponin for hydrolysis while extracting saponin, wherein directly carrying ...
|
|
WO/2020/069267A1 |
Provided herein are halogenated cholesterol analogues, including methods of making and using the same. Also provided are methods of making radiolabeled cholesterol analogues including admixing an epoxide with a fluorine-18 source under c...
|
|
WO/2020/062883A1 |
The present invention relates to a derivative based on an Anemarrhenae rhizome sarsasapogenin structure, wherein the structural formula thereof is as shown in general formula I, (I). Also provided are a pharmaceutical composition of the ...
|
|
WO/2020/068689A1 |
Described herein are terpinoid derivatives as NRF2 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of inflammatory diseases.
|
|
WO/2020/025942A1 |
Compounds of general formula (I): wherein R2a, R2b, R3a, R3b, R5, Y and R7 are as defined herein are selective agonists at the FXR receptor and are useful for the treatment or prevention of diseases and conditions including nonalcoholic ...
|
|
WO/2019/195692A1 |
wherein,R1, R2, R3, R4a, R4b and R5 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. ...
|
|
WO/2019/191637A1 |
Methods of preventing or retarding or reversing or abolishing the onset of Parkinson's and other neurodegenerative diseases are discussed.
|
|
WO/2019/173499A1 |
Disclosed are compounds suitable for enhancing cancer treatment, for example, a compound of formula (I): (I) wherein R1 is as defined herein. Also disclosed is a method of enhancing the response of cancer cells in a mammal to treatment w...
|
|
WO/2019/136487A2 |
Described herein protein steroid conjugates that are useful, for example, for the target-specific delivery of glucocorticoids (GCs) to cells.
|
|
WO/2019/129308A1 |
Provided is a method for recycling steroid epoxy isomer. Reacting with a reactive metal such as lithium, sodium, and potassium in an diphenyl organic solvent so as to reduce and form conjugated double bonds; in an alkaline environment, k...
|
|
WO/2019/129176A1 |
The present invention provides a sarsasapogenin derivative and a preparation method and application thereof. The derivative has a structure as shown in formula I, and the definition of each substituent is as described in the specificatio...
|
|
WO/2019/126741A1 |
Provided herein are compounds of Formula (I-I): and pharmaceutically acceptable salts thereof; wherein p, R1, R3a, R2a, R11a, R11b, R6a, and R6b are defined herein. Also provided herein are pharmaceutical compositions comprising a compou...
|
|
WO/2019/116070A1 |
The invention relates to compounds of formula (I), their method of synthesis as well as their use to treat neurodegenerative disorders.
|
|
WO/2019/090405A1 |
The invention disclosed herein is intended for the pharmaceutical industry and the area of medicine for combating flu, and relates to any medicinal-product composition that is characterized by containing ciclesonide in the composition th...
|
|
WO/2019/081586A1 |
The present invention relates to new and improved processes for the preparation of deoxycholic acid (DCA) and pharmaceutically acceptable salts thereof, as well as to DCA and pharmaceutically acceptable salts thereof, the carbon atoms of...
|
|
WO/2019/080571A1 |
The present invention provides a method for extracting toosendanin, comprising: first washing and drying melia azedarach bark or melia azedarach seeds, grinding, and performing extraction by using a cellulase and apectinase water solutio...
|
|
WO/2019/055493A1 |
A method for treating a mitogen activated protein kinase kinase/extracellular signal-regulated kinase ("MEK")-induced or an MEK-related pathology in a mammal, comprising administering a pharmaceutical composition containing an effective ...
|
|
WO/2019/023769A1 |
The present invention relates, most generally, to steroidal glycosides that can be used for treating skin disorders. Particularly, the invention relates to the use of certain steroidal glycosides, per se or in the form of aglycone, spiro...
|
|
WO/2019/021122A2 |
The present invention relates to novel Liver X Receptor (LXR) modulators, their use in diagnostic and therapy, more particularly in the treatment of diseases associated with LXR, such as cancer, inflammation, metabolic and autoimmune dis...
|
|
WO/2019/015914A1 |
The invention relates to a process for the preparation of obeticholic acid and derivatives thereof comprising: (a) hydrogenation of the double bond and reductive opening of the epoxide of a compound of formula (II) or a salt or solvate t...
|
|
WO/2019/006534A1 |
Methods, uses, compositions and kits for treating steroid-resistant chronic rhinosinusitis (CRS), including refractory CRS, in a subject, or for improving or restoring the response to anti- inflammatory sinus treatment in a patient suffe...
|
|
WO/2018/213077A1 |
Provided herein are compounds, compositions, conjugates and methods for the treatment of diseases, and/or conditions such as, but not limited to, proliferative diseases. In certain embodiments, compounds, compositions, and conjugates are...
|
|
WO/2018/201516A1 |
A compound and an application thereof for treatment of cataract. The structural formula of the compound is as shown in formula I. The compound of formula I, a prodrug thereof, or a pharmaceutically acceptable salt thereof, can be used to...
|
|
WO/2018/145162A1 |
The present invention relates to a new class of steroid saponins that have interesting biological activity. In particular the present invention relates to a class of steroid saponins in which the sugar moiety has been selectively functio...
|
|
WO/2018/089373A9 |
Described herein protein steroid conjugates whereby a glucocorticoid compound is conjugated to a binding agent which is preferably an antibody. These are useful, for example, for the target-specific delivery of glucocorticoids (GCs) to c...
|
|
WO/2018/121770A1 |
An antidepressant steroid compound and a preparation method and an application thereof; the structure of said compound is shown in formula (I), and the definition of each substituent is as described in the description and claims. The com...
|
|
WO/2018/033939A1 |
Disclosed herein is an improved process for the preparation of Budesonide using Perchloric acid catalyst in water as a major medium.
|
|
WO/2017/211820A1 |
The present invention relates to new and improved processes for the preparation of deoxycholic acid (DCA) and pharmaceutically acceptable salts thereof, as well as to novel intermediates useful for the preparation of DCA and pharmaceutic...
|
|
WO/2017/210471A1 |
Provided herein are glucocorticoid receptor agonist immunoconjugates, glucocorticoid receptor agonists, and methods of using the same, e.g., to treat autoimmune or inflammatory diseases.
|
|
WO/2017/199036A1 |
The invention relates to a process for preparing a compound of general formula (la): wherein R2, Y, R4and R5are as defined herein, wherein the epoxidation is conducted using an oxidant and methyltrioxorhenium as a catalyst (MeReO3). The ...
|
|
WO/2017/199033A1 |
The invention relates to compounds of general formula (I): wherein: R1,R2, R3, R4, R5, R6 and Y are as defined herein. The compounds are intermediates in the synthesis of synthetic bile acids which are useful in the treatment of conditio...
|
|
WO/2017/199039A1 |
The invention relates to a process for preparing a compound of general formula (Ia): wherein R2, Y, R4 and R5 are as defined herein. The invention also relates to certain compounds per se. The compounds are intermediates in the synthesis...
|
|
WO/2017/186135A1 |
Disclosed in the present invention are a compound and an application thereof for the treatment of cataracts. The structural formula of the compound is shown in formula I. The compound shown in formula I, a prodrug thereof, or a pharmaceu...
|
|
WO/2017/139485A1 |
Disclosed is a method of enhancing the response of cancer cells in a mammal to treatment with an apoptosis inducing ligand, which method comprises contacting the cancer cells with an apoptosis inducing ligand in conjunction with an effec...
|
|
WO/2017/134087A1 |
Steroidic calixarene compounds according to formula (I): (I) wherein: ∙ R represents -(CH2)x-L-(CH2)y-Ster, wherein : ○ x and y are integers comprised between 0 and 2; ○ n is an integer comprised between 1 and 5; ○ L represents a...
|
|
WO/2017/088080A1 |
The present invention relates to a method for obtaining and purifying saponins from plant extracts, which comprises extracting saponins and subsequently removing impurities by adding a salt selected from the group of alkaline earth metal...
|
|
WO/2017/053868A1 |
Disclosed herein are C4 modified oleanolic acid derivatives of the formula: Formula (X) or Formula (XII), as well as analogs thereof, wherein the variables are defined herein. In addition, disclosed herein are pharmaceutical compositions...
|
|
WO/2017/028397A1 |
The present invention provides a method for extracting peroxyergosterol from wall-broken ganoderma lucidum spore powder. The method comprises the steps of preparation of peroxyergosterol crude extract, medium-pressure preparative chromat...
|
|
WO/2017/021852A1 |
Method for the separation of at least one isoprenic constituent from the resin of a plant of guayule and/or of the guayule type comprising the steps of: a) providing a defatted resin of guayule and/or of the guayule type; b) subjecting t...
|
|
WO/2014/094032A9 |
The present invention relates to a new polymorphic form of the compound diosgenyl α-L-rhamnopyranosyl-(1->2)-β-D-glucopyranoside (compound (I)) and pharmaceutical compositions containing this polymorph
|
|
WO/2016/173524A1 |
Disclosed in the present application are the compounds as shown in formulae I, II, III, IV or V, tautomers thereof, stereoisomers thereof or pharmaceutically acceptable salts thereof, and also disclosed is the use thereof in preparing dr...
|
